Advertisement

PET studies in progressive supranuclear palsy

  • D. J. Brooks
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 42)

Summary

Functional imaging (PET and SPECT) can be used to noninvasively demonstrate the patterns of metabolic and dopaminergic dysfunction associated with progressive supranuclear palsy. In this chapter the findings of published functional imaging studies are reviewed and the value of PET for distinguishing between the various degenerative causes of parkinsonism is discussed.

Keywords

Positron Emission Tomography Progressive Supranuclear Palsy 18FDG Positron Emission Tomography Positron Emission Tomography Study Progressive Supranuclear Palsy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander GE, Delong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9: 357–381.PubMedCrossRefGoogle Scholar
  2. Baron JC, Maziere B, Loc’h C, et al (1986) Loss of striatal (76Br)bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 6: 131–136.PubMedCrossRefGoogle Scholar
  3. Bhatt MH, Snow BJ, Martin WRW, Peppard R, Calne DB (1991) Positron emission tomography in progressive supranuclear palsy. Arch Neurol 48: 389–391.PubMedCrossRefGoogle Scholar
  4. Blin J, Baron JC, Dubois P, et al (1990) Positron emission tomography study in progressive supranuclear palsy. Arch Neurol 47: 747–752.PubMedCrossRefGoogle Scholar
  5. Blin J, Vidhailhet M, Pillon B, et al (1992) Corticobasal degeneration: decreased and asymmetrical glucose consumption as studied by PET. Mov Disord 7: 348–354.PubMedCrossRefGoogle Scholar
  6. Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y (1984) 3H-spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 99: 167–175.PubMedCrossRefGoogle Scholar
  7. Brooks DJ, Ibañez V, Sawle GV, et al (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28: 547–555.PubMedCrossRefGoogle Scholar
  8. Brooks DJ, Ibañez V, Sawle GV, et al (1992) Striatal D2 receptor status in Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and PET. Ann Neurol 31: 184–192.PubMedCrossRefGoogle Scholar
  9. Burn DJ, Sawle GV, Brooks DJ (1993) The differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry (in press).Google Scholar
  10. Cortes R, Camps M, Gueye B, Probst A, Palacios JM (1989) Dopamine receptors in the human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 483: 30–38.PubMedCrossRefGoogle Scholar
  11. D’Antona R, Baron JC, Samson Y, et al (1985) Subcortical dementia: frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 108: 785–800.CrossRefGoogle Scholar
  12. De Voider AG, Francard J, Laterre C, et al (1989) Decreased glucose utilisation in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 26: 239–247.CrossRefGoogle Scholar
  13. Dubas F, Gray F, Escourolle R (1983) Maladie de Steele-Richardson-Olszewski sans ophthalmologie. Rev Neurol 139: 407–416.PubMedGoogle Scholar
  14. Eidelberg D, Dhawan V, Moeller JR, et al (1991) The metabolic landscape of corticobasal ganglionic degeneration: regional asymmetries studied with position emission tomography. J Neurol Neurosurg Psychiatry 54: 856–862.PubMedCrossRefGoogle Scholar
  15. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114: 2283–2301.PubMedCrossRefGoogle Scholar
  16. Fearnley JM, Revesz T, Brooks DJ, Frackowiak RSJ, Lees AJ (1991) Diffuse Lewy body disease presenting with a supranuclear downgaze palsy. J Neurol Neurosurg Psychiatry 54: 159–161.PubMedCrossRefGoogle Scholar
  17. Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA (1988) Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol 24: 399–406.PubMedCrossRefGoogle Scholar
  18. Foster NL, Gilman S, Berent S, et al (1992) Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry 55: 707–713.PubMedCrossRefGoogle Scholar
  19. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol 26: 507–514.PubMedCrossRefGoogle Scholar
  20. Gibb WRG, Luthert P, Marsden CD (1989) Corticobasal degeneration. Brain 112: 1171–1192.PubMedCrossRefGoogle Scholar
  21. Goffinet AM, De Voider AG, Gillain C, et al (1989) Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann Neurol 25: 131–139.PubMedCrossRefGoogle Scholar
  22. Goto S, Hirano A, Matsumoto S (1989) Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration. Ann Neurol 26: 766–770.PubMedCrossRefGoogle Scholar
  23. Guttman M, Seeman P (1986) Dopamine D2 receptor density in Parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy. Adv Neurol 46: 51–57.Google Scholar
  24. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) The accuracy of the clinical diagnosis of Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184.PubMedCrossRefGoogle Scholar
  25. Jackson JA, Jankovic J, Ford J (1983) Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 13: 273–278.PubMedCrossRefGoogle Scholar
  26. Jellinger K, Riederer P, Tomananga M (1980) Progressive supranuclear palsy: clinicopathological and biochemical studies. J Neural Transm [Suppl] 16: 111–128.Google Scholar
  27. Johnson KA, Sperling RA, Holman BL, Nagel JS, Growdon JH (1992) Cerebral perfusion in progressive supranuclear palsy. J Nucl Med 33: 704–709.PubMedGoogle Scholar
  28. Karbe H, Grond M, Huber M, Herholz K, Kessler J, Heiss WD (1992) Subcortical damage and cortical dysfunction in progressive supranuclear palsy demonstrated by positron emission tomography. J Neurol 239: 98–102.PubMedCrossRefGoogle Scholar
  29. Kish SJ, Chang LJ, Mirchandani LJ, Shannak K, Hornykiewicz O (1985) Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol 18: 530–536.PubMedCrossRefGoogle Scholar
  30. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med 318: 876–880.PubMedCrossRefGoogle Scholar
  31. Kiyosawa M, Baron JC, Hamel E, et al (1989) Time course of effects of unilateral lesions of the Nucleus Basalis of Meynert on glucose utilisation by the cerebral cortex. Positron emission tomography in baboons. Brain 112: 435–455.PubMedCrossRefGoogle Scholar
  32. Koeppen AH, Hans MB (1976) Supranuclear ophthalmoplegia in olivopontocerebellar degeneration. Neurology 26: 764–768.PubMedCrossRefGoogle Scholar
  33. Kuhl DE, Metter EJ, Benson DF, et al (1985) Similarities of cerebral glucose metabolism in Alzheimer’s and Parkinsonian dementia. J Cereb Blood Flow Metab 5[Suppl] 1: S169–S170.Google Scholar
  34. Kuhl DE, Metter EJ, Riege WH (1984) Patterns of local cerebral glucose utilisation determined in Parkinson’s disease by the 18F-fluorodeoxyglucose method. Ann Neurol 15: 419–424.PubMedCrossRefGoogle Scholar
  35. Laplane D, Levasseur M, Pillon B, et al (1989) Obsessive-compulsive and other behavioural changes with bilateral basal ganglia lesions. Brain 112: 699–725.PubMedCrossRefGoogle Scholar
  36. Leenders KL, Frackowiak RS, Lees AJ (1988) Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. Brain 111: 615–630.PubMedCrossRefGoogle Scholar
  37. Leenders KL, Palmer A, Turton D, et al (1986) DOPA uptake and dopamine receptor binding visualized in the human brain in vivo. In: Fahn S, Marsden CD, Jenner P, Teychenne P (eds) Recent developments in Parkinson’s disease. Raven Press, New York, pp 103–113.Google Scholar
  38. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O (1978) Receptor basis for dopaminergic supersensitivity in Parkinson disease. Nature 273: 59–60.PubMedCrossRefGoogle Scholar
  39. Lees AJ (1986) The Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). In: Marsden CD, Fahn S (eds) Movement disorders, vol 2. Butterworths, London, pp 273–287.Google Scholar
  40. Maher ER, Lees AJ (1986) The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 36: 1005–1008.PubMedCrossRefGoogle Scholar
  41. McCulloch J, MacKenzie ET, Cudennec A, Duverger D, Degueurce A, Scatton B (1984) Influences of the raphe nuclei on brain glucose utilisation. Soc Neurosci Abstr 10: 218.Google Scholar
  42. Miletich RS, Bankiewicz R, Plunkett R, et al (1988) L-[18F]6-Fluorodopa PET images of catecholaminergic tissue implants in hemi-parkinsonian monkeys. Neurology 38: S140–S145 (abstract).Google Scholar
  43. Perkin GD, Lees AJ, Stern GM, Kocen RS (1978) Problems in the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Can J Neurol Sci 6: 167–173.Google Scholar
  44. Pappata S, Mazoyer B, Tran Dinh S, Cambon H, Levasseur M, Baron JC (1990) Effects of capsular or thalamic stroke on metabolism in the cortex and cerebellum: a positron tomography study. Stroke 21: 519–524.PubMedCrossRefGoogle Scholar
  45. Pierot L, Desnos C, Blin J, et al (1988) Dl and D2-type dopamine receptors in patients with Parkinson’s disease and progressive supranuclear palsy. J Neurol Sci 86: 291–306.PubMedCrossRefGoogle Scholar
  46. Quik M, Spokes E, MacKay A, Bannister R (1979) Alterations in 3H-spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy Drager syndrome and Parkinson’s disease. J Neurol Sci 43: 429–437.PubMedCrossRefGoogle Scholar
  47. Rajput AH, Rozdilsky B, Rajput A (1991) Accuracy of clinical diagnosis in Parkin-sonism — a prospective study. Can J Neurol Sci 18: 275–278.PubMedGoogle Scholar
  48. Riley DE, Lang AE, Lewis A, et al (1990) Cortical-basal ganglionic degeneration. Neurology 40: 1203–1212.PubMedCrossRefGoogle Scholar
  49. Ross-Russell R (1980) Supranuclear palsy of eyelid closure. Brain 103: 71–82.CrossRefGoogle Scholar
  50. Ruberg M, Javoy-Agid F, Hirsch E, et al (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol 18: 523–529.PubMedCrossRefGoogle Scholar
  51. Savaki HE, Graham DI, Grome JJ, McCulloch J (1984) Functional consequences of unilateral lesion of the locus coeruleus: a quantitative [14C]2-deoxyglucose investigation. Brain Res 292: 239–249.PubMedCrossRefGoogle Scholar
  52. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RSJ (1991) Corticobasal degeneration: a unique pattern of regional cortical oxygen metabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 114: 541–556.PubMedCrossRefGoogle Scholar
  53. Steele JC, Richardson JC, Olszewski J (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia, and cerebellum, with vertical gaze and pseudobulbar palsy. Arch Neurol 10: 333–359.PubMedCrossRefGoogle Scholar
  54. Taniwaki T, Hosokawa S, Goto I, et al (1992) Positron emission tomography (PET) in “pure akinesia”. J Neurol Sci 107: 34–39.PubMedCrossRefGoogle Scholar
  55. Wienhard K, Coenen HH, Pawlik G, et al (1990) PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system. J Neural Transm [Gen Sect] 81: 195–213.CrossRefGoogle Scholar
  56. Will RG, Lees AJ, Gibb W, Barnard RO (1988) A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome. J Neurol Neurosurg Psychiatry 51: 1224–1227.PubMedCrossRefGoogle Scholar
  57. Wolfson LI, Leenders KL, Brown LL, Jones T (1985) Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson’s disease. Neurology 35: 1399–1405.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1994

Authors and Affiliations

  • D. J. Brooks
    • 1
  1. 1.MRC Cyclotron UnitHammersmith HospitalLondonUK

Personalised recommendations